• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Berenstein Israel Yakov was granted 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

    12/26/24 7:42:06 AM ET
    $NITO
    Agricultural Chemicals
    Industrials
    Get the next $NITO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Berenstein Israel Yakov

    (Last) (First) (Middle)
    SHEVET LEVI 13

    (Street)
    PETACH TIKVA L3 4930092

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    N2OFF, Inc. [ NITO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/23/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Restricted Shares of Common Stock 12/23/2024 A 50,000(1) A $0 64,500 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These restricted shares of common were issued to the Reporting Person in accordance with the Save Foods, Inc. 2022 Share Incentive Plan.
    /s/ Israel Berenshtein 12/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NITO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NITO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NITO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Silberman Alon claimed ownership of 454,127 shares (SEC Form 3)

    3 - N2OFF, Inc. (0001789192) (Issuer)

    10/28/25 4:05:14 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    New insider Scisparc Ltd. claimed ownership of 490,751 shares (SEC Form 3)

    3 - N2OFF, Inc. (0001789192) (Issuer)

    10/24/25 4:05:27 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    Chief Financial Officer Barda Lital was granted 300,000 units of Restricted Shares of Common Stock (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    5/12/25 4:10:18 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    SEC Filings

    View All

    SEC Form DEF 14A filed by N2OFF Inc.

    DEF 14A - N2OFF, Inc. (0001789192) (Filer)

    11/3/25 4:05:27 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    SEC Form SCHEDULE 13G filed by N2OFF Inc.

    SCHEDULE 13G - N2OFF, Inc. (0001789192) (Subject)

    10/24/25 4:06:27 PM ET
    $NITO
    Agricultural Chemicals
    Industrials

    SEC Form PRE 14A filed by N2OFF Inc.

    PRE 14A - N2OFF, Inc. (0001789192) (Filer)

    10/24/25 9:00:03 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rosenbloom Ronen bought 50,000 units of Restricted Shares of Common Stock, increasing direct ownership by 345% to 64,500 units (SEC Form 4)

    4 - N2OFF, Inc. (0001789192) (Issuer)

    12/26/24 7:42:11 AM ET
    $NITO
    Agricultural Chemicals
    Industrials

    $NITO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    N2OFF Completed Merger with Cancer Drug Discovery Company Targeting Tough-to-Treat Pancreatic and Lung Cancers

    Neve Yarak, Israel, Oct. 30, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced the closing of the merger with MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's pr

    10/30/25 9:25:00 AM ET
    $NITO
    $SPRC
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

    TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the closing of the sale to N2OFF, Inc. (NASDAQ:NITO) ("N2OFF") of SciSparc's majority owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX").  MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's proprietary algorithm that enables reliable 3D comparative modeling of mitochon

    10/23/25 4:03:00 PM ET
    $NITO
    $SPRC
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    N2OFF Announces Closing of Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

    Neve Yarak, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ:NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, announced today the closing of the merger with MitoCareX Bio Ltd. ("MitoCareX"), a biotech company focused on drug discovery targeting cancer therapeutics, with a range of other potential diseases and disorders, through targeting the mitochondrial SLC25 protein family. MitoCareX is focusing on the development of novel therapies for hard-to-treat cancers by targeting proteins belonging to the mitochondrial SLC25 protein family. Central to this effort is MITOLINE™, MitoCareX's propr

    10/23/25 8:25:00 AM ET
    $NITO
    $SPRC
    Agricultural Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NITO
    Financials

    Live finance-specific insights

    View All

    N2OFF Announces Strategic Initiatives Intended to Maximize Shareholder Value

    Neve Yarak, Israel, Oct. 02, 2024 (GLOBE NEWSWIRE) -- N2OFF, Inc.\ (NASDAQ:NITO) (FSE:80W) ("N2OFF" or the "Company"), a clean tech company engaged in sustainable solutions for the energy and agri-tech industries, announced today key strategic initiatives approved by its board of directors (the "Board") that are intended to increase shareholder value. Key Highlights of the Board's Initiatives Spin-off of cleantech activities: N2OFF is considering pursuing a potential spin-off of its cleantech operations - NTWO OFF Ltd. and Save Foods Ltd. – into a separate publicly traded company with the intention of listing that spin-off company on a national exchange. In connection with the potential

    10/2/24 8:30:00 AM ET
    $NITO
    Agricultural Chemicals
    Industrials